口服高剂量醋酸甲羟孕酮（MPA）与美替奥斯坦治疗绝经后晚期乳腺癌的III期试验。
A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer.
作者信息
Izuo M, Yoshida M, Tominaga T, Abe O, Enomoto K, Nomura Y, Kubo K, Takatani O
出版信息
Cancer. 1985 Dec 1;56(11):2576-9. doi: 10.1002/1097-0142(19851201)56:11<2576::aid-cncr2820561107>3.0.co;2-i.
A randomized controlled trial was performed to compare the therapeutic results of oral high-dose medroxyprogesterone acetate (HD-MPA) versus mepitiostane (MS) in the treatment of postmenopausal breast cancer. MPA was given at three doses of 400 mg orally daily to 47 patients and produced objective responses in 19 cases (40.4%). An objective response was seen in 14 of the 40 control patients given MS at two doses of 10 mg orally daily (35.0%). Among patients with bone metastases, 6 of 19 (31.6%) for HD-MPA and 2 of 13 (15.4%) for MS showed objective responses. The other merits of HD-MPA suggested in the study were improvement in performance status, increase in appetite, and myeloprotective effect.
进行了一项随机对照试验，以比较口服高剂量醋酸甲羟孕酮（HD-MPA）与美替司坦（MS）治疗绝经后乳腺癌的疗效。47例患者每日口服3种剂量（400mg）的甲羟孕酮，19例（40.4%）产生客观缓解。40例接受每日口服2种剂量（10mg）美替司坦的对照患者中，14例（35.0%）出现客观缓解。在有骨转移的患者中，HD-MPA组19例中有6例（31.6%）、MS组13例中有2例（15.4%）出现客观缓解。该研究表明，HD-MPA的其他优点包括改善身体状况、增加食欲和骨髓保护作用。
Zotero 插件